Drugs / Erythropoietin alpha
Erythropoietin alpha
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05585658 | Oct → Nov 2021 | poisoning | Globe Biotech Limited | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT01868477 | Jan 2014 → Mar 2017 | myelodysplastic syndrome | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00286182 | Jul 2007 → Nov 2012 | anemia | Mathew S. Maurer | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT00425698 Comparator | Feb 2007 → May 2009 | — | Hannover Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02031289 Comparator | Dec 2013 → Dec 2017 | anemia, disorder of iron metabolism and transport | University of Zurich | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erythropoietin alpha | “Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc.” NCT02031289 ↗ |
| Known as | Eprex | “Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc.” NCT02031289 ↗ |
| Known as | Erythropoietin alpha (Epogen) | “Erythropoietin alpha (Epogen)” NCT00286182 ↗ |
| Known as | rHuEPO alpha | “Recombinant erythropoietin alpha (rHuEPO alpha)” NCT00425698 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human EPO (rHuEPO)” NCT00425698 ↗ |
| Route | Subcutaneous | “Erythropoietin alpha is administered weekly by subcutaneous injection” NCT00286182 ↗ |